Related to Merck Dampens 2013 Expectations After Q4 Profits Slide

• Biotech Companies Face the Key Question—Deal or No Deal?
  Advice: Set aside dreams of becoming the next Amgen or Genentech; instead know when to partner, take the money, and run.
  
• BioTrends 2009: Execs Provide Tips on How to Prepare for Changing Times
  Survival strategies and the most profitable options are discussed.
  
• Improving Working Capital—The Next Step in Big Pharma’s Transformation Efforts
  Better management of working capital could help firms get a better return rather than just driving top-line growth.
  
• Mergers and Acquisitions—The New IPO
  Tips for a strong communication strategy that will lure shareholders and investors over to your side.
  
• Virtual Development Models Become Biopharma’s Efficiency Initiative
  Such a strategy allows drug development to be driven by scientific data rather than a company’s survival or long-term stability.
  
• When Is Revenue Not Revenue for Biotech Firms?
  Proposed changes in accounting rules highlight complexity for public companies.
  
• BIO Investor: IPOs, Financing, and the Need for New Flu Treatments
  Presenters believe that M&A will shift to deals between biotech firms and that new technologies will improve vaccine production.
  
• How Biotech Unions Could Save Companies and Revitalize Pipelines
  Impetus for such mergers comes from the drying up of venture funds and pharma consolidation.
  
• New Uncertainty Regarding Disclosure of Adverse Effects
  Recent Matrixx Initiatives decision muddies requirements set forth in Carter-Wallace over a decade ago.
  
• Early-Stage Investors Hedge Their Bets with Medical Devices
  VCs are looking for a quicker return on their investments with less risk involved.
  
• Reporting from J.P. Morgan Healthcare Conference
  Drug companies developing companion diagnostics is just one of the trends highlighted at the meeting.
  
• Biotech Financing Overview and Trends from Last Year’s Fourth Quarter
  Biotechs are lining up to go public after a long wait.
  
• What Will Succeed Lipitor as the Next Blockbuster Cholesterol-Lowering Drug?
  CETP inhibitors are vying to take over from statins, but one major failure hovers ominously.
  
• Marketing Innovations for Biotechs to Increase Revenues
  Looking outside the industry can bring breakthroughs.
  
• A Look at the Top Two Bio Clusters in the U.S.: California and Massachusetts
  Financing and workforce issues are at the top of their agendas for this year.
  
• Overview of the Number Three and Four Biotech Clusters in the U.S.
  North Carolina and Maryland are trying to start new funds to support start-ups.
  
• Review of the Second Tier of Biotechnology Clusters in the U.S.
  Colorado, Florida, New Jersey, Pennsylvania, and Washington gear up to boost growth plans while trying to balance budget woes.
  
• Supreme Court’s Decision in Matrixx v. Siracusano Calls for More Disclosure of Adverse Events to Investors
  Side effects that are not statistically significant must also be divulged.
  
• NY Biotech Leaders Pursue Empire State of Mind with One-Stop Shop Proposal
  Think tank is also promoting tax credit extensions, tailored incentives, and easier tech transfer as cures for state’s life science blues.
  
• More VC But Fewer Deals Signal That Investors Are Becoming Even More Risk Averse
  While the love affair may be ending, venture capitalists are still opening up their wallets to later-stage companies.